Synthetic Cell Technology Could Benefit Vaccine Production, Venter Says
J. Craig Venter's synthetic cell may dramatically speed up vaccine production, he told a Congressional committee
You may also be interested in...
The former Celera CEO has raised $70 million for a new organization that will use genomic, biochemical and microbiome data to find stem cell-based treatments for aging-related disorders.
FDA has been holding the world body to the same standards it uses for a regular drug review, resulting in many years of delay in bringing artesunate rectal suppositories to market - but the Anti-Infective Drugs Advisory Committee has given a partial endorsement.
Protein Sciences' seasonal influenza vaccine FluBlok has typical immunity data but some manufacturing issues.